1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Mesalamine (5-aminosalicylic acid, 5-ASA) |
| brand | String | Asacol HD, Pentasa, Lialda, Apriso, Delzicol, Rowasa (rectal), Canasa (suppository) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:5-aminosalicylates|5-aminosalicylate (5-ASA)]] • [[:Category:IBD_medications|IBD medication]] • [[:Category:Anti-inflammatories|Anti-inflammatory]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"' |
| starting_dose | String | Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis |
| preparations | String | Multiple non-bioequivalent oral formulations (pH-, time-, and moisture-dependent release); rectal enema 4 g/60 mL; 1 g rectal suppository |
| fda_max | String | Formulation-specific; ~4.8 g/d typical maximum oral |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • rectal |
| onset | String | Symptomatic improvement 2-4 weeks |
| duration | String | 24 hours (most ER formulations) |
| halflife | String | ~5-10 hours (5-ASA)'"`UNIQ--ref-00000BBE-QINU`"' |
| bioavailability | String | Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"' |
| pregnancy | String | Generally considered safe at standard doses; benefits typically outweigh in active IBD.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
